Research Article

Disease Modifying Therapies for Alzheimer’s Disease Targeting A\textbeta{} Oligomers: Implications for Therapeutic Mechanisms

Etsuro Matsubara,\textsuperscript{1} Ayumi Takamura,\textsuperscript{1,2} Yasuhide Okamoto,\textsuperscript{3} Hideto Oono,\textsuperscript{1} Takashi Nakata,\textsuperscript{1} Yasuhide Wakasaya,\textsuperscript{1} Takeshi Kawarabayashi,\textsuperscript{1} and Mikio Shoji\textsuperscript{1}

\textsuperscript{1}Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Aomori 036-8562, Japan
\textsuperscript{2}Shin-Yurigaoka General Hospital, Kanagawa 215-0026, Japan
\textsuperscript{3}Imumas Pharma Incorporation, Kanagawa 213-0012, Japan

Correspondence should be addressed to Etsuro Matsubara; etsuro@cc.hirosaki-u.ac.jp

Received 30 April 2013; Revised 22 July 2013; Accepted 22 July 2013

Academic Editor: Patrick Kehoe

Copyright © 2013 Etsuro Matsubara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Several lines of evidence indicate that amyloid $\beta$ (A$\beta$), particularly A$\beta$ oligomers (A$\beta$Os), plays a causative role in Alzheimer’s disease. However, the mechanisms underlying the action of an anti-A$\beta$O antibody to clarify the toxic action of A$\beta$Os remain elusive. Here, we showed that the anti-A$\beta$O antibody (monoclonal 72D9) can modify the A$\beta$ aggregation pathway. We also found that 72D9 directly sequesters both extracellular and intraneuronal A$\beta$Os in a nontoxic state. Thus, therapeutic intervention targeting A$\beta$Os is a promising strategy for neuronal protection in Alzheimer’s disease.

1. Introduction

Disease modifying therapies for Alzheimer’s disease (AD) are based on strategic approaches towards the “amyloid cascade hypothesis” [1]. Among them, what appears to meet our expectation is A$\beta$ immunotherapy, which involves immune-mediated A$\beta$ deplation in the brain [2–5]. However, recent phase III trials of certain A$\beta$ monoclonal antibodies (e.g., bapineuzumab and solanezumab) failed to significantly slow cognitive and functional declines. Despite the disappointing outcomes, the effects of both antibodies were confirmed on biomarkers (http://www.alzforum.org/new/detail.asp?id=3268, http://www.alzforum.org/new/detail.asp?id=3442). From this point of view, A$\beta$ immunotherapy is now considered as prophylaxis for patients with mild cognitive impairment. Indeed, solanezumab is now being evaluated in terms of its efficacy for antiamyloid treatment in an asymptomatic Alzheimer’s disease (A4) prevention clinical trial (http://www.alzforum.org/new/detail.asp?id=3379).

Accumulated lines of evidence indicate that memory loss represents a synaptic failure caused directly by soluble A$\beta$Os [6–9] and that amyloid fibrils may cause neuronal injury indirectly via microglial activation [10]. Thus, the classical amyloid cascade hypothesis [1] underwent a modification in which emphasis was switched to intermediate forms of A$\beta$ such as A$\beta$Os [11–15], rather than fibrillar A$\beta$ [10]. Therapeutic intervention targeting A$\beta$Os alone should be a promising strategy for AD treatment [16, 17]. Several major hypotheses underlying the action of A$\beta$ immunotherapy have been proposed, including phagocytosis by microglia [18], peripheral sink [19], neonatal Fc receptor (FcRn) mediated A$\beta$ transport across the blood-brain barrier (BBB) [20], catalytic modification of A$\beta$ fibrils [21], intracerebral sequestration of A$\beta$ in a monomeric state [22], and antibody-mediated neutralization of A$\beta$Os and/or tau toxicity [23]. However, the precise molecular mechanisms underlying disease modifying therapy targeting A$\beta$Os remain elusive. Here, among the abovementioned hypothetic mechanisms, the last issue with particular emphasis on the action of an anti-A$\beta$O antibody was evaluated. We found that the anti-A$\beta$O antibody (72D9) can modify the A$\beta$ aggregation pathway and that it directly sequesters both extracellular and intraneuronal A$\beta$Os in a nontoxic state.
2. Materials and Methods

2.1. Antibodies. Monoclonal 72D9 was generated and characterized as described previously [17]. Polyclonal A11 specific to AβOs was purchased from BioSource (Camarillo, CA, USA). Goat anti-mouse IgG conjugated with Alexa Fluor (AF) 488 or 594 and goat anti-rat IgG conjugated with AF 488 were purchased from Molecular Probes (Eugene, OR, USA). Anti-mouse IgG2b (the IgG2b isotype) was purchased from Sigma (St. Louis, MO, USA).

2.2. Aβ Incubation and ThT Assay. ThT assay was performed as described previously [24]. Aβ solutions at 12.5 μM were incubated with Abs (72D9 and IgG2b) at the indicated concentration and at 37°C for 24 h. The ThT fluorescence intensity in the incubation mixtures was determined using a spectrofluorophotometer (RF-5300PC) (Shimadzu Co., Kyoto, Japan). The optimum fluorescence intensity of amyloid fibrils was measured at excitation and emission wavelengths of 446 and 490 nm, respectively, with a reaction mixture (1.0 mL) containing 5 μM ThT and 50 mM glycine-NaOH at pH 8.5. Fluorescence intensity was measured immediately after preparing the mixture.

2.3. Aβ-Induced Toxicity Assay. We conducted the Aβ-induced toxicity assay in the presence or absence of Abs according to previously published methods [24]. Briefly, human neuroblastoma SH-SY5Y cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated horse serum (Invitrogen) and 5% FBS (Invitrogen). Basically, toxicity was assessed using Aβ1-42 at 12.5 μM with (0, 0.5, 1.0, and 1.5 μM) and without Abs for 24 h at 37°C. Toxicity was assessed by LDH assay in accordance with the manufacturer’s instructions (Molecular Probes, Eugene, OR, USA).

2.4. Electron Microscopy (EM). For electron microscopy, samples were diluted with 0.1% distilled ammonia solution and spread on carbon coated grids. The grids were negatively stained with 1% phosphotungstic acid and examined under a Hitachi H-7000 electron microscope (Tokyo, Japan) at an acceleration voltage of 77 kV.

2.5. Double Immunolabeling and Confocal Laser Microscopy. To elucidate the ability of 72D9 for the intracerebral sequestration of AβOs, paraffin-embedded mouse brain sections from 72D9- and IgG2b-treated 3xTg-AD mice (n = 6, each) [17] were immunolabeled with Alexa Fluor-conjugated secondary antibodies (green). AβOs were immunolabeled with A11, which was detected with Alexa Fluor-conjugated secondary antibodies (red), and nucleases, with the antibody against DAPI, which was detected with Alexa Fluor-conjugated secondary antibodies (blue). Sections were imaged using a confocal laser scanning microscope (Carl Zeiss LSM510).

3. Results and Discussion

3.1. Modification of the Aβ Aggregation Pathway. Our previous in vivo experiments using 72D9 resulted in a marked reduction in the density of Gallyas-Braak positive senile plaques in 3xTg-AD mice with improved cognition [17]. Since 72D9 does not recognize Aβ fibrils, microglial phagocytosis was not observed [17], indicating that 72D9 can modify the Aβ aggregation pathway in vivo. To assess this issue, we incubated 12.5 μM seed-free Aβ42 alone or with antibodies at 37°C for 24 h. As shown in Figure 1(a), ThT fluorescence intensity decreased with the increasing 72D9 concentration, and nonspecific IgG2b showed no antifibrillogenic activity.
Figure 2: Antitoxic activity of 72D9. (a) SH-SY5Y cells were exposed to 12.5 μM seed-free Aβ42 with control IgG2b or 72D9 at 37°C for 24 h. Level of LDH released from SH-SY5Y cells treated for 24 h with 12.5 μM Aβ1-42 with control IgG2b or 72D9 at the indicated concentrations (0, 0.5, 1.0, and 1.5 μM). Each value indicates the percent level of LDH released following treatment with incubation mixtures relative to the level of LDH released following treatment with Triton X-100. Each column indicates average ± SD. The P value was determined by one-way ANOVA, followed by Tukey test for post hoc analysis: statistical significance compared with Aβ1-42 alone (* P < 0.0001). (b) Sections of control 72D9-treated or IgG2b-treated 3xTg-AD mouse brain were analyzed by immunofluorescence imaging of 72D9 (green), polyclonal A11 (red), and DAPI (blue). Inset: representative higher magnification images are shown in the insets of panels (d) and (e).
Using EM (Figure 1(b)), we find Aβ fibrils in the presence of IgG2b; however, a mixture of Aβ fibrils and nonfibrillar amorphous Aβ structures was observed in the presence of 72D9. In support of our findings, a similar modification of the Aβ aggregation pathway using antibody fragments is reported by three groups, who proposed that antibody fragments withdraw AβOs from the Aβ amyloid fibril-forming pathway, maintaining them in nonfibrillar amorphous structures [25–28]. From a structural viewpoint, it has been shown that bapineuzumab captures Aβ in a monomeric helical conformation at the N-terminus [29]. Another intracerebral sequestration of Aβ in a monomeric state to prevent further Aβ assembly and related neurotoxicity is also reported by m266.2, a parent of the humanized monoclonal antibody solanezumab [22]. However, these two mechanisms are not the case for 72D9, because 72D9 does not recognize Aβ monomers [17]. Thus, our data indicate that 72D9 prefers to lead AβOs to form nonfibrillar amorphous structures in a chaperone-like manner, which allow AβOs to exist in a nontoxic state.

3.2. Intracerebral Sequestration of AβOs in a Nontoxic State. From the abovementioned functional viewpoint on AβOs, we further characterized the antitoxic activity of 72D9 in vitro. SH-SYSY cells were incubated at 37°C for 24 h with 12.5 μM seed-free Aβ42 with or without antibodies. Compared with vehicle treatment, LDH assay of SH-SYSY cells revealed significant neuronal death in the presence of nonspecific IgG2b (Figure 2(a)). In contrast, monoclonal 72D9 afforded nearly complete blockade of the neurotoxicity of the peptide assembly in a concentration-dependent manner (Figure 2(a)), which is in good agreement with our previous finding [17]. Regarding this action, in vitro experiments demonstrated that conformation-dependent antibodies [30–35] and their fragments [28] successfully immunoneutralized the toxicity of AβOs. Presently, there is no evidence that antibody-AβO interactions induce nontoxic conformational changes. In our previous experiment [17], sortilin is upregulated in the presence of AβOs, and sortilin-p75NTR receptors are formed on neuronal membranes; however, the downregulation of sortilin and the dissociation of sortilin from p75NTR occur by the direct sequestration of AβOs in the presence of 72D9. Through this mechanism, extracellular AβOs appear to be maintained in a nontoxic state when complexed with 72D9.

To further assess the above issue, we reevaluated the brains of the mice with improved cognition that received 72D9 immunotherapy [17]. Of note, we found that 72D9 decorated neurons in the brain parenchyma of 3x-Tg AD mice at 26 months of age (Figure 2(b)); this was not the case in the control IgG2b-immunized 3x-Tg AD mice of the same age (Figure 2(c)). Thus, some 72D9 got across BBB and directly immunoneutralized AβOs in the brain parenchyma. Triple labeling analysis revealed that 72D9 and Aβ1-42 immunofluorescences overlap in the cytosol of neurons, indicating that 72D9 can be internalized into neurons together with AβOs (Figure 2(b)). Tampellini et al. [36] showed that anti-Aβ antibodies bind to the extracellular Aβ domain of the amyloid precursor protein (APP) and are internalized together with APP, followed by the clearance of intraneuronal Aβ via the endosomal-lysosomal pathway. Since 72D9 does not cross-react with APP [17], another yet unknown mechanism drives this internalization. Of note, most of the 72D9-negative pyramidal neurons exhibited atypical, eccentric large nuclei with abnormal chromatin morphology and distributions, features indicative of impending neuronal degeneration (Figure 2(e)). Such abnormalities were less evident in the 72D9-positive pyramidal neurons (Figure 2(d)), indicating that internalized AβO as a complex with 72D9 appears to be maintained in a nontoxic state. Although the precise mechanisms for resolving this issue should be clarified in future studies, note that 72D9 can sequester both extracellular and intraneuronal AβOs in a nontoxic state.

4. Conclusions

Because AβO immunotherapy is promising for preemptive disease modifying therapy, research aimed at elucidating the molecular mechanisms underlying the action of AβOs and/or antibodies targeting AβOs is clearly required. The purpose of our study was to evaluate this issue. We herein found that an anti-AβO antibody plays an important role in the Aβ aggregation pathway in a chaperone-like manner and the intracerebral sequestration of AβOs in a nontoxic state, which is responsible for neuronal protection.

Conflict of Interests

Yasuhide Okamoto is an employee of Immunus Pharma Incorporation. Etsuro Matsubara is a coinventor of two filed provisional patent applications entitled “Antibody Specific Binding to a Beta Oligomer and The Use” and “Antibodies That Specifically Bind to Aβ Oligomers and Uses Thereof,” which cover the antibody described in this paper, but this does not alter the adherence to all the Journal of Biomedicine and Biotechnology policies on sharing data and materials. This study has in some parts been funded by a commercial funder, but that does not alter the authors’ adherence to all the Journal of Biomedicine and Biotechnology policies on sharing data and materials.

Acknowledgments

This work was supported in part by a Grant-in-Aid for Advanced Brain Scientific project from the Ministry of Education, Culture, Sports, Science and Technology, Japan, (15016080 and 16015284 to Etsuro Matsubara); a Research Grant for Longevity Sciences from the Ministry of Health, Labour and Welfare (17A-1 to Etsuro Matsubara); a grant from the Ministry of Health, Labour and Welfare (Research on Dementia, Health, and Labor Sciences Research Grants H20-006 and H20-007 to Etsuro Matsubara); and a grant from the Karoji Memorial Fund for the Medical Research.
References


